ALFUZOSINE LP TEVA HEALTH 10 mg

Generic drug of Xatral LP
Therapeutic class: Urology nephrology
active ingredients: Alfuzosin
laboratory: Teva Sante

Sustained release tablet
Box of 30
All forms

Indication

· Treatment of functional symptoms of benign prostatic hypertrophy.

· Adjunctive bladder catheterization in acute urine retention related to benign prostatic hypertrophy.

Dosage ALFUZOSINE LP TEVA HEALTH 10 mg Prolonged release tablet Box of 30

Oral way.

The tablet should be swallowed whole, without crimping, with a glass of water (see Warnings and Precautions ).

adults

The recommended dosage is 1 10 mg tablet daily, to be taken immediately after the evening meal.

Adjuvant bladder catheterization in acute urine retention related to benign prostatic hypertrophy:

The recommended dosage is 1 10 mg tablet daily, to be taken after the meal, from the first day of urethral catheterization.

The treatment is administered for 3 to 4 days including 2 to 3 days during the catheterization and 1 day after the withdrawal of the latter.

Against indications

Hypersensitivity to alfuzosin and / or any of the excipients

· Orthostatic hypotension

· Hepatic insufficiency

· Severe renal insufficiency (creatinine clearance <30 ml / min)

· Combination with potent CYP3A4 inhibitors (see section Interactions with other medicinal products and other forms of interaction ).

Adverse effects Alfuzosine LP Teva Sante

FREQUENCY
ORGAN SYSTEM	Frequent (≥1% - <10%)	Rare (≥0.1% - <1%)	Very rare (<0.01%)
CNS disorders and psychiatric disorders	dizziness, dizziness, malaise, headache	dizziness, drowsiness
Cardiovascular disorders		tachycardia, palpitations, orthostatic hypotension, syncope	Angina pectoris in patients with a history of coronary heart disease (see Warnings and Precautions section )
Respiratory system disorders		Nasal congestion
Gastrointestinal disorders	nausea, abdominal pain	diarrhea, dry mouth
Skin manifestations		rashes, pruritus	Urticaria, angioneurotic edema
General events	asthenia	flushes, edema, chest pain (see section Warnings and precautions for use )
	FREQUENCY
ORGAN SYSTEM	Frequent (≥1% - <10%)	Rare (≥0.1% - <1%)	Very rare (<0.01%)
CNS disorders and psychiatric disorders	dizziness, dizziness, vertigo, malaise, headache	drowsiness
Visual disorders		abnormal vision
Cardiovascular disorders	orthostatic hypotension	tachycardia, palpitations, syncope	Angina pectoris in patients with a history of coronary heart disease (see Warnings and Precautions section )
Respiratory system disorders		Nasal congestion
Gastrointestinal disorders	nausea, abdominal pain, diarrhea, dry mouth
Skin manifestations		rashes, pruritus	Urticaria, angioneurotic edema
General events	asthenia	flushes, edema, chest pain (see section Warnings and precautions for use )

Reporting of suspected adverse reactions

The reporting of suspected adverse reactions after authorization of the drug is important. It allows continuous monitoring of the benefit / risk ratio of the drug. Health professionals declare any suspected adverse reaction via the national reporting system: National Agency for the Safety of Medicines and Health Products (Ansm) and the network of Regional Pharmacovigilance Centers - Website: www.ansm.sante.fr.